Clearside raises $20M; Egalet nixes Shionogi deal;

@FierceBiotech: Pfizer is shuttering another U.K. R&D outpost, ditching 120 jobs. Article | Follow @FierceBiotech

@JohnCFierce: Lilly pulls the plug on a massive insulin project in a blow to its diabetes pipeline. Story | Follow @JohnCFierce

@DamianFierce: this is good SEO. Link | Follow @DamianFierce

> Clearside Biomedical closed a $20 million Series C financing to support its work on micro-injected treatments for back-of-the-eye diseases. News

> Novo Nordisk ($NVO) filed for European approval for a fast-acting version of its insulin NovoLog. More

> Egalet ($EGLT) terminated its collaboration with Shionogi, regaining the rights to a Phase I hydrocodone treatment designed to discourage abuse. Release

Medical Device News

@FierceMedDev: Dx Digest: Report | Follow @FierceMedDev

@VarunSaxena2: I've never seen a team invent so many ways to lose as the Detroit Lions! I knew it was coming! Unsure of call but it's the Lions after all. | Follow @VarunSaxena2

@EmilyWFierce: Google Life Sciences CMO opens up about research plans. Story | Follow @EmilyWFierce

> NIH funds a trio of robots to improve health, life quality for the disabled. Report

> Troubled Insulet recalling additional 18 lots of wearable insulin pump due to needle failure. More

Pharma News

@FiercePharma: #ICYMI yesterday: $TEVA to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters. Story | Follow @FiercePharma

@CarlyHFierce: Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s. Story | Follow @CarlyHFierce

> If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says. More

> Cancer drug prices vary across the globe as countries strike deals with Big Pharma: Study. Report

> Sun to launch copy of Novartis' best-selling drug Gleevec Feb. 1. Story

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera